

6. LITERATUR

1. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial (no authors listed). *Lancet*. 1996; 348: 633-638.
2. Albers GW, Dalen JE, Laupacis A et al. Antithrombotic Therapy in Atrial Fibrillation. *CHEST*. 2001; 119: 194S-206S.
3. Albers GW, Diener HC, Frison L et al. SPORTIF Executive Committee for the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. *JAMA*. 2005; 293: 690-698.
4. Al-Khadra AS, Salem DN, Rand WM et al. Warfarin Anticoagulation and Survival : A Cohort Analysis from the Studies of Left Ventricular Dysfunction. *J Am Coll Cardiol*. 1998; 31: 749-753.
5. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. *JAMA*. 1999; 282: 2058-2067.
6. Ansell J, Völler H, Hasenkam JM. International Self-Monitoring Association for Oral Anticoagulation. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. *Int J Cardiol*. 2005; 99: 37-45.
7. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled trials. *Arch Intern Med*. 1994; 154: 1449-1457.
8. Azar AJ, Cannegieter SC, Deckers JW et al. Optimal Intensity of Oral Anticoagulant Therapy After Myocardial Infarction. *J Am Coll Cardiol*. 1996; 27: 1349-1355.
9. Baker DW, Wright RF. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. *JAMA*. 1994; 272: 1614-1618.
10. Becker RC. Antithrombotic Therapy after Myocardial Infarction. *N Engl J Med*. 2002; 347: 1019-1022.
11. Bittner V, Weiner DH, Yusuf S et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. *JAMA*. 1993; 270: 1702-1707.
12. Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N Engl J Med*. 1995; 333: 11-17.

13. Carson PE, Johnson GR, Dunkman WB et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. *Circulation*. 1993; 87: VI 102-110.
14. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet*. 1999; 353: 9-13.
15. Cioffi G, Pozzoli M, Forni G et al. Systemic thromboembolism in chronic heart failure. A prospective Study in 406 patients. *Eur Heart J*. 1996; 17: 1381-1389.
16. Cleland JGF, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart failure (WASH): A randomised trial comparing antithrombotic strategies for patients with heart failure. *Am Heart J*. 2004; 148: 157-164.
17. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomised Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. *N Engl J Med*. 2001; 345: 1667-1675.
18. Cokkinos DV, Toutouzas PK. Antithrombotic therapy in heart failure : a randomized comparison of warfarin vs. aspirin (HELAS). *Eur J Heart Fail*. 1999; 1: 419-423.
19. Connolly SJ. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. *Am Heart J*. 2003; 145: 418-423.
20. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med*. 1987; 316: 1429-1435.
21. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet*. 1997; 350: 389-396.
22. Davis CJ, Gurbel PA, Gattis WA et al. Hemostatic abnormalities in patients with congestive heart failure : diagnostic significance and clinical challenge. *Int J Cardiol*. 2000; 75: 15-21.
23. De Lorenzo F, Saba N, Kakkar VV. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. *Drugs*. 2003; 63: 565-576.
24. De Mets DL, Califf RM. Lessons Learned From Recent Cardiovascular Clinical Trials : Part I. *Circulation*. 2002; 106: 746.
25. Diet F, Erdmann E. Antikoagulation bei Herzinsuffizienz. *Internist*. 2000; 41: 276-282.
26. Diet F, Erdmann E. Thromboembolism in heart failure: who should be treated? *Eur J Heart Fail*. 2000; 2: 355-363.
27. Doval HC, Nul DR, Grancelli HO et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. *Circulation*. 1996; 94: 3198-3203.

28. Dries DL, Domanski MJ, Waclawiw MA et al. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. *Am J Cardiol.* 1997; 79: 909-913.
29. Dries DL, Rosenberg YD, Waclawiw MA et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. *J Am Coll Cardiol.* 1997; 29: 1074-1080.
30. Dunkman WB. Thromboembolism and antithrombotic therapy in congestive heart failure. *J Cardiovasc Risk.* 1995; 2: 107-117.
31. Dunkman WB, Johnson GR, Carson PE et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Study Group. *Circulation.* 1993; 87: VI 94-101.
32. Echemann M, Alla F, Briancon S et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL Study). *Eur J Heart Fail.* 2002; 4: 647-654.
33. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. *Lancet.* 2003; 362: 1691-1698.
34. Feinglass J, Martin GJ, Lin E et al. Is heart failure survival improving? Evidence from 2323 elderly patients hospitalised between 1989-2000. *Am Heart J.* 2003; 146: 111-114.
35. Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. *Ann Intern Med.* 1996; 124: 970-979.
36. Fiore LD, Ezekowitz MD, Brophy MT et al. for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin with Aspirin Alone in Survivors of Acute Myocardial Infarction. *Circulation.* 2002; 105: 557-563.
37. Fuster et al. ACC/ AHA/ ESC Guidelines for the Management of Patients with Atrial Fibrillation. *J Am Coll Cardiol.* 2001; 38: 1231-1365.
38. Gallus AS, Baker RI, Chong BH et al. on behalf of the Australasian Society of Thrombosis and Haemostasis. Consensus guidelines for warfarin therapy. *MJA.* 2000; 172: 600-605.

39. Gitt AK, Wasserman K, Kilkowski C et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. *Circulation*. 2002; 106: 3079-3084.
40. Gornick CC. Anticoagulant use in nonvalvular atrial fibrillation. Determining risk and choosing the safest course. *Postgrad Med*. 2000; 108: 113-116, 119-121, 125-126.
41. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs. adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern Med*. 1998; 158: 1513-1521.
42. Haass M, Zugck C, Kübler W. Der 6-Minuten-Gehtest: Eine kostengünstige Alternative zur Spiroergometrie bei Patienten mit chronischer Herzinsuffizienz? *Z Kardiol*. 2000; 2: 72-80.
43. Hach-Wunderle V, Neuhaus KL. *Thrombolyse und Antikoagulation in der Kardiologie*. Springer-Verlag, Berlin Heidelberg, 1994.
44. Hirsh J, Fuster V, Ansell J et al. American Heart Association/ American College of Cardiology Foundation Guide to Warfarin Therapy. *Circulation*. 2003; 107: 1692-1711.
45. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalisations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA*. 2000; 283: 1295-1302.
46. Ho KK, Anderson KM, Kannel WB et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*. 1993; 88: 107-115.
47. Hohnloser SH, Connolly SJ. Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. *J Cardiovasc Electrophysiol*. 2003; 14: S60-63.
48. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation- Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. *Lancet*. 2000; 356: 1789-1794.
49. Hunt SA; ACC/ AHA Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). http://www.escardio.org/Knowledge/Guidelines/Chronic_Heart_Failure.htm.
50. Hunt SA, Baker DW, Chin MH et al. ACC/ AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines 2001. http://www.acc.org/clinical/guidelines/failure/hf_index.htm.
51. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med*. 2002; 347: 969-974.

52. Hylek EM, Skates SJ, Sheehan MA et al. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation. *N Engl J Med.* 1996; 335: 540-546.
53. Jafri SM, Ozawa T, Mammen E et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. *Eur Heart J.* 1993; 14: 205-212.
54. Jessup M, Brozena S. Heart Failure. *N Engl J Med.* 2003; 348: 2007-2018.
55. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? *J Cardiovasc Risk.* 1995; 2: 97-102.
56. Kearney MT, Fox KA, Lee AJ et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. *J Am Coll Cardiol.* 2002; 40: 1801-1808.
57. Kleber FX. The predictive value of cardiorespiratory fitness. *Eur Heart J.* 2004; 25: 1374-1375.
58. Komajda M, Follath F, Swedberg K et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. *Eur Heart J.* 2003; 24: 464-474.
59. Koniaris LS, Goldhaber SZ. Anticoagulation in dilated cardiomyopathy. *J Am Coll Cardiol.* 1998; 31: 745-748.
60. Kortke H, Minami K, Breymann T et al. INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial). *Z Kardiol.* 2001; 90 Suppl.6: 118-124.
61. Lee WM, Larrey D, Olsson R et al. Hepatic findings in long-term clinical trial of ximelagatran. *Drug Saf.* 2005; 28: 351-370.
62. Levy D, Kenchaiah S, Larson MG et al. Long-Term Trends in the Incidence of and Survival with Heart Failure. *N Engl J Med.* 2002; 347: 1397-1402.
63. Lip GYH, Gibbs CR. Anticoagulation for heart failure in sinus rhythm (Cochrane Review). In: *The Cochrane Library.* 2003, Issue 3, Oxford: Update Software.
64. Lip GYH, Gibbs CR. Does Heart Failure Confer A Hypercoagulable State? Virchows Triad Revisited. *J Am Coll Cardiol.* 1999; 33: 1424-1426.
65. Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime Risk for Developing Congestive Heart Failure. The Framingham Heart Study. *Circulation.* 2002; 106: 3068.
66. Loh E, Sutton MSJ, Wun CC et al. Ventricular Dysfunction and the Risk of Stroke after Myocardial Infarction. *N Engl J Med.* 1997; 336: 251-257.
67. MacCarthy PA, Kearney MT, Nolan J et al. Prognosis in heart failure with preserved left ventricular systolic dysfunction : prospective cohort study. *BMJ.* 2003; 327: 78-79.

68. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. *J Am Coll Cardiol.* 2001; 37: 569-578.
69. Massie BM. Aspirin use in chronic heart failure: what should we recommend to the practitioner? *J Am Coll Cardiol.* 2005; 46: 963-966.
70. Massie BM, Krol WF, Ammon SE et al. The Warfarin and Antiplatelet Therapie in Heart Failure trial (WATCH): rationale, design and baseline patient characteristics. *J Card Fail.* 2004; 10: 101-112.
71. Mc Kelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomised evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. *Circulation.* 1999; 100: 1056-1064.
72. Mc Kenzie DB, Cowley AJ. Drug therapy in chronic heart failure. *Postgrad Med J.* 2003; 79: 634-642.
73. Mc Murray JJ, Pfeffer MA. New Therapeutic Options in Congestive Heart Failure: Part II. *Circulation.* 2002; 105: 2223-2228.
74. Mc Murray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. *Heart* 2000; 83: 596-602.
75. Mohr JP, Thompson JLP, Lazar RM et al. for the Warfarin-Aspirin Recurrent Stroke Study Group. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke. *N Engl J Med.* 2001; 345: 1444-1451.
76. Moss AJ, Zarebe W, Hall WJ et al. for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. *N Engl J Med.* 2002; 346: 877-883.
77. Natterson PD, Stevenson WG, Saxon LA et al. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. *Am Heart J.* 1995; 129: 564-570.
78. Nolan J, Batin PD, Andrews R et al. Prospective study of heart rate variability and mortality in chronic heart failure : results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). *Circulation.* 1998; 98: 1510-1516.
79. Packer M, Bristow MR, Cohn JN et al. The Effect of Carvedilol on Mortality in Patients with Chronic Heart Failure. *N Engl J Med.* 1996; 334: 1349-1355.
80. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N Engl J Med.* 1991; 325: 1468-1475.

81. Packer M, Coats AJS, Fowler MB et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of Carvedilol Survival in Severe Chronic Heart Failure. *N Engl J Med.* 2001; 344: 1651-1658.
82. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med.* 1992; 327: 669-677.
83. Pfeffer MA, Swedberg K, Granger CB et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet.* 2003; 362: 759-766.
84. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure randomised trial- the Losartan Heart Failure Survival Study ELITE II. *Lancet.* 2000; 355: 1582-1587.
85. Pitt B, Remme WJ, Zannad F et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. *N Engl J Med.* 2003; 348: 1309-1321.
86. Pitt B, Zannad F, Remme WJ et al. for The Randomized Aldactone Evaluation Study Investigators. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. *N Engl J Med.* 1999; 341: 709-717.
87. Ponikowski P, Anker SD, Chua TP et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol.* 1997; 79: 1645-1650.
88. Remme WJ for the European Society of Cardiology. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. *Eur Heart J.* 1997; 18: 736-753.
89. Remme WJ, Swedberg K: Task Force for the Diagnosis and Treatment of Chronic Heart Failure, ESC. Guidelines for the diagnosis and treatment of chronic heart failure. *Eur Heart J.* 2001; 22: 1527-1560.
90. Salukke TV, Dimopoulos K, Francis D. Cardiac resynchronisation may reduce all-cause mortality: meta-analysis of preliminary COMPANION data with CONTAK-CD, InSync ICD, MIRACLE and MUSTIC. *Int J Cardiol.* 2004; 93: 101-103.
91. Siaplaouras S, Heisch A, Buob A et al. Antikoagulation zur Primärprophylaxe thromboembolischer Ereignisse bei fortgeschrittener linksventrikulärer Funktionseinschränkung. *Med Klin.* 2001; 96: 281-286.
92. Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. *Thromb Haemost.* 2004; 91: 225-232.

93. Sirajuddin RA, Miller AB, Geraci SA. Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: a critical literature review. *J Card Fail.* 2002; 8: 48-53.
94. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. *N Engl J Med.* 1990; 323: 147-152.
95. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med.* 1992; 327: 685-691.
96. Sosin MD, Bhatia G, Davis RC et al. Congestive heart failure and Virchow's triad: a neglected association. *Wien Med Wochenschr.* 2003; 153: 411-416.
97. Stewart S, MacIntyre K, Hole DJ et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. *Eur J Heart Fail.* 2001; 3: 315-322.
98. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. *Circulation.* 1991; 84: 527-539.
99. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. *Arch Intern Med.* 1996; 156: 409-416.
100. Teerlink JR, Jalaluddin M, Anderson S et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. *Circulation.* 2000; 101: 40-46.
101. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework (no authors listed). *Lancet.* 1998; 351: 233-241.
102. Trampisch HJ, Windeler J. *Medizinische Statistik.* Springer-Verlag Berlin Heidelberg, 1997.
103. van den Broek SA, van Veldhuisen DJ, de Graeff PA et al. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol.* 1992; 70: 359-363.
104. van der Meer FJ, Rosendaal FR, Vandenbroucke JP et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. *Arch Intern Med.* 1993; 153: 1557-1562.
105. van Es RF, Jonker JJC, Verheugt FWA et al. for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research

- Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet*. 2002; 360: 109-113.
106. Van Gelder IC, Hagens VE, Bosker HA et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A Comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med*. 2002; 347: 1834-1840.
107. Van Walraven C, Hart RG, Singer DE et al. Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in. *Card Electrophysiol Rev*. 2003; 7: 374-378.
108. Van Walraven C, Hart RG, Wells GA et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. *Arch Intern Med*. 2003; 163: 936-943.
109. Wallentin L, Wilcox RG, Weaver WD et al. for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. *Lancet*. 2003; 362: 789-797.
110. WASH study Steering Committee and Investigators. The WASH Study (Warfarin/ Aspirin Study in Heart failure) rationale, design and end-points. *Eur J Heart Fail*. 1999; 1: 95-99.
111. Wichter T, Breithardt G. Antikoagulation bei Herzinsuffizienz und linksventrikulärer Dysfunktion. *Dtsch med Wochenschr*. 2002; 127: 2145-2148.
112. Wyse DG, Waldo AL, Di Marco JP et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. *N Engl J Med*. 2002; 347: 1825-1833.
113. Young JB, Abraham WT, Smith AL et al.; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. *JAMA*. 2003; 289: 2685-2694.
114. Yusuf S, Pitt B. A Lifetime of Prevention. The Case of Heart Failure. *Circulation*. 2002; 106: 2997.